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  EVIDENCE-BASED ANSWER 
With adults, oral theophylline may help lower the dosage of inhaled steroids needed to control chronic asthma. 
It offers no benefit for acute asthma exacerbations. For children, intravenous aminophylline may improve the 
clinical course of severe asthma attacks. Side effects and toxicity limit use of these medications in most 
settings. (Grade of recommendation: A, based on systematic reviews and randomized control trials [RCTs]). 
  EVIDENCE SUMMARY 
Several systematic reviews help clarify theophylline’s role in asthma management. When compared with 
placebo in the management of acute exacerbations, theophylline confers no added benefit to beta-agonist 
therapy (with or without steroids) in improving pulmonary function or reducing hospitalization rates. Side effects 
occurred more often in the theophylline group: palpitations/arrhythmias (OR = 2.9; 95% CI: 1.5 to 5.7) and 
vomiting (OR = 4.2; 95% CI: 2.4 to 7.4).1 For moderately severe asthma in patients already receiving inhaled 
corticosteroids (ICS), theophylline as maintenance therapy equaled long-acting beta-2-agonists in increasing 
FEV 1 and PEFR, but was less effective in controlling night time symptoms. Use of long-acting beta-agonists 
resulted in fewer side effects (RR = 0.38; 95%CI: 0.25-0.57).2 When added to low-dose ICS for maintenance, 
theophylline was as effective as high-dose ICS alone in improving FEV 1 , decreasing day and night symptoms, 
and reducing the need for rescue medications and the incidence of attacks. This suggests theophylline has 
utility as a steroid sparing agent.3 
Intravenous aminophylline does appear to be clinically beneficial for children with severe exacerbations, defined 
as an FEV 1 of 35%-40% of predicted value. Critically ill children receiving aminophylline in addition to usual 
care exhibited an improved FEV 1 at 24 hours (mean difference = 8.4%; 95% CI: 0.82 to 15.92) and reduced 
symptom scores at 6 hours.4 The largest RCT of aminophylline in children demonstrated a reduced intubation 
rate (NNT = 14 CI: 7.8-77).5 Children receiving aminophylline experienced more vomiting (RR = 3.69; 95%CI: 
2.15-6.33). Treatment with aminophylline did not reduce length of hospital stay or the number of rescue 
nebulizers needed (Table).4 
 
TABLE 
Theophylline use in asthma 
  Adults Children 
Acute 
Treatment 
No added benefit to 
corticosteroids and beta-
agonist therapy; increased GI 
and cardiac side effects. 
24 hours of IV 
aminophylline improves 
symptom scores without 
reducing LOS or nebulizer 
requirements; may reduce 
intubation 
Maintenance Therapy   Mild No clinical benefit Not recommended 
      Moderate Performs worse than long-
acting beta-agonists and has 
more side effects; may limit 
the need for high-dose ICS if 
not using long beta agonists. 
No advantage over long-
acting beta agonists when 
added to ICS. More side 
effects 
  Severe Same for moderate; does not 
limit the need for oral 
corticosteroids in this setting. 
Same as moderate 
LOS = length of stay; ICS = inhaled corticosteroids. 
  RECOMMENDATIONS FROM OTHERS 
Three evidence-supported guidelines concur that theophylline has a limited role as maintenance therapy for 
moderate-to-severe persistent asthma when symptom control with ICS alone is not adequate. Much stronger 
evidence supports the use of long-acting beta-2-agonists or leukotriene modifiers in this setting.6-8 The 
guidelines do not recommend using theophylline to treat acute asthma exacerbations; nor do they address 
using theophylline in children. 
Read a Clinical Commentary by M. Lee Chambliss, MD, MSPH, at www.fpin.org. 
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